Bridging gaps in care with artificial intelligence
As US payers and providers struggle with a fragmented healthcare system, patients with chronic conditions continue to experience gaps in…
Senior medication adherence: the growing problem
By the year 2030 the entire Baby Boomer generation will be age 65 or older. This growing number of senior…
Improving diabetes adherence: pharmacies, Medicare Advantage Plans and AI
In the field of chronic diseases, Type 2 diabetes ranks high when it comes to the challenges of therapy initiation…
Advances in patient interventions: How to manage complexity
Patient adherence programs are continually searching for more cost-effective interventions that improve clinical outcomes. Tactics have expanded beyond outreach by…
The challenge of mental health drug non-adherence
Major mental health disorders are some of the most difficult conditions to manage. According to a retrospective analysis in Systematic…
Overcoming adherence barriers in oral anticancer medications
Over the past decade, treatment in a variety of cancers, particularly breast cancer, chronic myelogenous leukemia, and non-small cell lung…
AllazoHealth now offers AI optimized therapy initiation
AllazoHealth continues to lead in advancing the use of artificial intelligence in healthcare. Building on our success in medication adherence,…
AllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory board
AllazoHealth, a company that uses artificial intelligence to help pharmaceuticals, payers, and pharmacies improve medication adherence and quality outcomes, announced…
COVID-19: Impact on medication adherence in 2020
2020 was dominated by the COVID-19 pandemic, and it will continue to dominate healthcare conversations this year. Looking back, how…
The new administration: Healthcare policy predictions
As the days tick down to the inauguration of President-elect Joseph Biden and Vice President-elect Kamala Harris, what will be…
Specialty drugs: the challenge of therapy initiation
AllazoHealth’s VP, Business Development Dev Mukherjee recently answered questions about specialty medications and the challenges faced by pharmaceutical companies and…
“Adherence Intelligence” is the new AI
How recognizing the unique characteristics of each patient optimizes resources and maximizes impact Medication non-adherence is an age-old problem that…
DIR contracts: How to prioritize for maximum value
AllazoHealth’s William Grambley, Chief Operating Officer, and Dr. Linda Schultz, VP, Clinical and Customer Success, address the factors that pharmacies…
Patient intervention: Effective tactics for pharmacies, payers and pharma
When it comes to patient intervention programs to promote adherence, what are the best tactics? The right answer may be…
Patient intervention data for pharma, payers and pharmacies: FAQ
AllazoHealth CEO Clifford Jones and Chief Operating Officer William Grambley recently answered questions about patient intervention data: what it is,…
Two recent studies show smart pill bottles have positive impact
How is the Pharmaceutical Industry Addressing Medication Adherence?
Artificial intelligence: What it is and what it’s not
There are a lot of companies that claim they offer solutions that are powered by artificial intelligence (AI) and/or machine…
